This comparison using Turkey’s method for post hoc comparison, again demonstrated that the small molecule PAP-1 improved stroke outcomes, while the peptidic KV1.3 blocker ShK-223, did not significantly reduce infarction (Supplementary Figure S1C) or improved neurological deficit (Supplementary Figure S1D). This evidence concerns the gene KCNA3 and stroke disorder.